Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study
Authors:
- 12 December 2024
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-4
Abstract
Bimekizumab, is the most recent monoclonal antibody licensed for the management of moderate-to-severe plaque psoriasis, acting through the dual inhibition of interleukin (IL)-17 A and IL17F, setting it apart from other anti-IL17 biologics. To date, long-term data on the use of bimekizumab for the management of plaque psoriasis in a real-world setting are scant. The aim of our study was to evaluate the effectiveness and safety of bimekizumab in long-term. A monocentric prospective study enrolling patients with moderate-to-severe plaque psoriasis undergoing treatment with bimekizumab for plaque psoriasis and with a follow-up of at least one year was performed. At baseline, demographic and clinical data were collected. Clinical data were evaluated at each follow-up visit [week (W)16-36-52]. A total of 43 patients respected the inclusion and exclusion criteria. At baseline, mean PASI and DLQI were 17.4 ± 8.3 and 24.1 ± 5.3, respectively. A statistically significant improvement of both scores was reported since W16 (PASI: 0.8 ± 1.4; DLQI: 0.9 ± 1.5, p < 0.0001), continuing to improve up to W52 (PASI: 0.4 ± 0.7; DLQI: 0.2 ± 0.4, p < 0.0001 (Table 1), with 33 (76.7%) and 29 (67.4%) subjects reaching PASI90/100 response at W16, and 36 (83.7%) and 31 (72.1%) patients achieving these results at W52. Regarding safety data, 3 (7.0%) eczematous reaction and 4 (9.3%) candidiasis were collected, with 1 patient developing both events at the same time. A total of 6 (14.0%) patients interrupted treatment: 4 (9.3%) for adverse events and 2 (4.6%) for treatment failure, respectively. Our experience confirmed the effectiveness and safety of bimekizumab in real-life, also in long-term, suggesting this drug as a valuable in the therapeutic landscape of psoriatic disease.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis)Journal of Dermatological Treatment, 2024
- Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective studyJournal of the American Academy of Dermatology, 2024
- Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)Dermatology Practical & Conceptual, 2024
- Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experiencedClinical and Experimental Dermatology, 2024
- Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective studyJournal of the American Academy of Dermatology, 2024
- Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)Frontiers in Medicine, 2023
- A case of erythrodermic psoriasis rapidly and successfully treated with BimekizumabJournal of Cosmetic Dermatology, 2022
- Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialBritish Journal of Dermatology, 2022
- Bimekizumab for the Treatment of PsoriasisDrugs, 2021
- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialThe Lancet, 2021